Good morning, ladies and gentlemen. My name is Elle, and I will be your operator today. Welcome to Knight Therapeutics' First Quarter 2025 Results Conference Call. Before turning the call over to Samira Sakhia, President and CEO of Knight, listeners are reminded that portions of today's discussion, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared. The company cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information or future events, except as required by law. We would also like to remind you that questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department via email to ir@knightpx.com or via phone at 514-484-4483. I would like to remind everyone that this call is being recorded today, May 8, 2025, and would now like to turn the meeting over to your host for today's call, Samira Sakhia. Please go ahead, Ms. Sakhia. Thank you, Elle. Good morning, everyone, and welcome to Knight Therapeutics' first quarter 2025 conference call. I'm joined on today's call with Amal Khouri, our Chief Business Officer, and Arvind Utchanah, our Chief Financial Officer. I'm pleased to announce that for the three months ended March 31, 2025, we reported revenues of CAD 88 million and an adjusted EBITDA of over CAD 12 million. Our revenues increased by CAD 2 million, or 3%, over the same period last year. The increase was mainly driven by our promoted portfolio, which accounts for over 75% of our total revenues. During the quarter, this portfolio grew by CAD 9 million, or 16%, on a constant currency basis. In addition, we continue to execute on the business development front. As previously announced, we entered into an agreement with Endo to acquire all of the assets of Paladin for CAD 100 million, plus CAD 20 million of inventory. Furthermore, Knight may pay future contingent payments of up to $15 million upon achievement of certain milestones. Also, we have expanded our relationship with Helsinn with the addition of Onacit for certain LatAm countries. Onicit is used for the prevention of chemotherapy-induced nausea and vomiting, as well as the prevention of postoperative nausea and vomiting. Moving to our pipeline, we continue to advance our portfolio with the regulatory submission of Tapiales in Argentina and the regulatory approval of Pemazyre in Mexico. In addition to the regulatory process during the quarter, we launched Minjuvi in Mexico and relaunched Onacit in Brazil and Mexico. Onto the NCIB. During the quarter, we purchased 605,000 common shares under the NCIB at an average purchase price of CAD 5.53 for aggregate cash consideration of CAD 3.3 million. I will now turn the call over to Arvind to provide an update on our financial results. Thank you, Samira. When speaking of our financial results, I will refer to adjusted EBITDA and financial results at constant currency, which are non-IFRS measures, as well as adjusted EBITDA per share, which is a non-IFRS ratio. Knight defines adjusted EBITDA as operating income or loss, excluding amortization and impairment of non-current assets, depreciation, the impact of accounting under hyperinflation, and acquisition and transaction cost, but to include costs related to leases. We define adjusted EBITDA per share as adjusted EBITDA over the number of common shares outstanding at the end of the respective period. In addition, revenues and financial results at constant currency are also non-GAAP measures. Financial results at constant currency are obtained by translating the prior period results at the average foreign exchange rates in effect during the current period, except for Argentina, where we only exclude hyperinflation. Furthermore, my discussion on the operating results will refer to figures that exclude hyperinflation unless otherwise indicated. For the first quarter of 2025, we delivered revenues of CAD 88 million, representing an increase of CAD 2 million or 3% versus Q1 last year. On a constant currency basis, revenues increased by CAD 6.6 million or 8%, driven by the growth of our key promoted products, partly offset by declines in our mature products. In the first quarter of 2025, our oncology and hematology portfolio delivered CAD 32 million of revenues, a growth of CAD 1 million or 3%. On a constant currency basis, the portfolio grew by CAD 2 million or 6% compared to the same period last year. This increase was driven by the continued growth of our key promoted brands, which contributed CAD 4 million of incremental revenues, mainly coming from Lenvima, Akinzeo, Trelstar, Minjuvi, as well as the addition of Onacit. This growth was partially offset by a decline in our mature and branded-generic products due to the life cycle and the market entrance of new competitors, as well as the impact of LatAm currency depreciation. Our infectious disease portfolio delivered CAD 36 million, a decrease of CAD 2 million or 4%. On a constant currency basis, the portfolio actually grew by CAD 1 million or 3% compared to the same period last year. The increase was due to purchasing patterns of certain customers, including Ambisome deliveries to the Ministry of Health in Brazil or MoH. As a reminder, in January 2025, we signed a third contract with the MoH, and we expect to deliver CAD 22.4 million in 2025, of which CAD 13 million were already delivered in Q1 compared to CAD 9 million in Q1 2024. Turning to our other specialty therapeutics areas, the portfolio generated CAD 20 million in revenues, representing an increase of CAD 3 million or 18%, mainly driven by the launch of Imvexxy and Bijuva in Canada, as well as purchasing patterns of certain customers. Now moving on to gross margin, we reported CAD 41 million or a gross margin percent of 47% of revenues in the first quarter of 2025, remaining relatively unchanged compared to the same period last year. I will now turn to our operating expenses, excluding amortization. For the first quarter, our operating expenses were CAD 30.2 million and increased of CAD 3 million or 10% compared to the same period last year. The increase in operating expenses was driven by an increase in commercial spend and structure behind our new launches, including Minjuvi, Imvexxy, Bijuva, and Jornay PM, as well as transaction fees related to the acquisition of Paladin. Moving on to adjusted EBITDA. For the first quarter of 2025, we reported $12.1 million of adjusted EBITDA, a decrease of $1.5 million or 11% compared to the same period last year. Our adjusted EBITDA per share was $0.12, a decrease of 8% compared to the same period last year. I will now cover our financial assets, which were valued at $127 million. During the quarter, we recorded a total net loss of $3.8 million on our financial assets, driven by the mark-to-market revaluation of our strategic fund investments and the change in value of certain equities. As a reminder, our funds continue to be a source of cash, and for the first quarter, we received a distribution of $3 million. Moving on to our cash flows. At the end of Q1, we held $141 million in cash and marketable securities. During the quarter, we generated cash inflows from operations of CAD 3.7 million and invested CAD 11.5 million in working capital, driven by an increase in our accounts receivable due to the timing of collections from certain customers. In addition, at the end of the quarter, our inventory was valued at CAD 140 million, an increase of CAD 37 million compared to the end of 2024. This investment is due to the growth of our portfolio, including our recent launches, as well as timing of orders and deliveries of certain products, including Ambisome to the Ministry of Health. Subsequent to the quarter, we closed a $40 million working capital line of credit from Citibank, of which we have withdrawn $35 million. The maturity date of the debt is at the end of September of this year. The proceeds from the line of credit will be used to settle the accounts payable for the inventory purchase during the first quarter. I will now turn the call back to Samira. Thank you, Arvind. Onto our financial outlook for fiscal 2025. I would like to remind everyone that this guidance includes the assumption that we will close the Paladin acquisition in the middle of 2025 and also assumes that there is no material adjustment due to hyperinflation accounting in Argentina. In addition, our guidance is based on a number of assumptions which are described in our press release. Should any of these assumptions differ, the financial outlook and actual results may vary materially. We are reconfirming our outlook for fiscal 2025 and expect to generate revenues between CAD 390 million-CAD 405 million and adjusted EBITDA of approximately 13% of revenues. Looking ahead, we are very excited that we can deliver to our stakeholders with our recent and upcoming launches, as well as our pipeline products. In addition, the Paladin transaction, which we expect to close in the middle of this year, will add critical mass and significantly increase the size of our Canadian business while adding a portfolio of stable cash flow generating products that will help fund our growth in Canada and Latin America. The Paladin transaction and the addition of Onacit demonstrate our focused execution in building a balanced portfolio that includes innovative, growing promoted products and mature cash flow generating assets. We remain well positioned to continue to execute on our mission to acquire, in-license, develop, and commercialize pharmaceutical products in Latin America and Canada. Thank you for your support and confidence in the Knight team. This concludes our formal remarks. I'd like to open up the call for questions. Thank you. Over to you, Elle. Before we begin, may I please remind you questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department via email to ir@knightpx.com or via phone at 514-484-4483. If you would like to ask a question, please press star followed by the number one on your telephone keypad. If you are using a speakerphone, please lift your handset before pressing any key. If you would like to withdraw your question, please press star two key. One moment, please, for your first question. Your first question comes from Michael Freeman of Raymond James. Please go ahead. Hey, good morning, Samira, Amal, Arvind. Congratulations on a strong quarter. I wonder if I have a few questions here. I wonder if you could, just thinking about your SG&A levels, how should we be thinking about your SG&A going forward, thinking and using this quarter's level? Should we be using it as a base going forward, or should we expect higher or lower? Of course, mid-year, we should expect Paladin to be included in these financials. I wonder if you could describe a bit of the SG&A contribution you might expect from that acquisition. Sure. As you know, we do not provide guidance on OPEX. What we have provided in the guidance that we have is revenue and then EBITDA margin. The guidance that we have provided includes closing Paladin in the middle of the year. If you, and we do not guide on a quarter-by-quarter basis. Spending can be a bit lumpy. It is fine. We are going to end the year with CAD 390 million-CAD 405 million of top line and EBITDA margin of 13%, and the OPEX will move to deliver on those results. Okay. All right. Thanks very much. I wonder just on the Paladin acquisition process, I wonder if you could provide any updates relating to how that deal is progressing, sort of more closing details, perhaps with a finer point than mid-year? We do not really have anything more than just kind of that mid-year. There is regulatory consent as well as regular consents that would be required, standard consents that would be required on a transaction like this. Each of those is progressing to plan. We believe that we will be in the timelines that we forecasted. Okay. That's great. If I could shoehorn just one more, I wonder if you could comment on typical seasonality across your jurisdictions. We saw a steady year-over-year growth, but of course, we saw a quarter-over-quarter dip. I wonder if you could just review the factors that impact the seasonality. Sure. I'm going to say the place that we have normal seasonality is Canada, where Q4 is usually a bigger quarter. We see buying patterns from wholesalers that load in advance. There's a little bit in Brazil, and a little bit in Brazil impacts our business more given the size of that business in our business today. The rest of the markets are pretty even, so there isn't that much seasonality. The reason I kind of bring this up is because as we add Paladin, we will start to see more seasonality in our business because it'll be a bigger contributor. Okay. Thank you very much. I'll pass it on now. Again, if you would like to ask a question, please press star followed by the number one on your telephone keypad. There are no further questions at this time. Please continue, Ms. Sakhia. Thank you. Once again, thank you for the confidence in the Knight team and for joining our Q1 2025 conference call. Have a great morning. Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.